Wellness & Workforce Solution for Lupus/Lupus Nephritis
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Morehouse School of Medicine
- Study ID
- NCT06217107
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Micro-learning content — BEHAVIORALThis is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
- Health360x app — BEHAVIORALThe coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
- Culturally congruent coaching — BEHAVIORALThe coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
Study Details
The investigators will test the hypothesis that culturally congruent coaching delivered via a technology application (Health360x) will improve the persistent disparities observed among women of color with lupus or lupus nephritis by addressing underlying psychosocial barriers to behavioral change.
Key Dates
- First listed
- Jan 22, 2024
- Start date
- Sep 14, 2024
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: C3 Coach plus H360xArm 1 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months.
- Active Comparator: C3 Coach plus Health360x and micro-learningArm 2 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions, in addition to periodic micro-learning content delivered via an online technology platform. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months. This arm will have learning augmented by micro-learning to test effectiveness in enhancing engagement and promoting retention of educational content.
Primary Outcome Measure
engagement [ Time Frame: Baseline, 3, 6 months ]
Central Contacts
- Carmel Ibeawuchi, MBA404-752-1664
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Morehouse School of Medicine | Atlanta | Georgia | 30310 | Priscilla Pemu, MD MS, FACP (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Atlanta, GA
By condition
By specialty
By research site
Related Studies
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPHASE2 · Recruiting · Hoffmann-La Roche · Loma Linda, California
- VIBRANT: VIB4920 for Active Lupus NephritisPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California
- The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPHASE2 · Recruiting · Children's Hospital Medical Center, Cincinnati · San Francisco, California
- Lupus Landmark Study: A Prospective Registry and BiorepositoryRecruiting · Lupus Research Alliance · Birmingham, Alabama